利拉鲁肽联合短期胰岛素强化治疗初诊肥胖2型糖尿病的临床疗效及对患者炎症因子的影响

Clinical efficacy of liraglutide combined with short-term insulin intensive treatment for newly diagnosed obese type 2 diabetes mellitus and its effect on inflammatory factors

目的 探讨利拉鲁肽联合短期胰岛素强化治疗初诊肥胖2型糖尿病的临床疗效及对患者炎症因子的影响。方法 选取2018年6月至2020年6月本院收治的92例初诊肥胖2型糖尿病患者作为研究对象,采用随机数字表法分为观察组与对照组,每组46例。对照组采用短期胰岛素强化治疗,观察组在对照组基础上联合利拉鲁肽治疗。比较两组治疗前、治疗1个月后血糖水平[空腹血糖(FBG)、餐后2 h血糖(2 h PBG)]、炎症因子[肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)]水平及不良反应发生情况。结果 观察组FBG(5.96±0.93)mmol/L、2 h PBG(7.28±1.25)mmol/L、TNF-α(56.16±8.07)ng/L、IL-6(311.87±28.51)ng/L,均低于对照组的(7.38±1.25)mmol/L、(9.31±1.46)mmol/L、(68.24±10.74)ng/L、(602.14±41.48)ng/L,差异有统计学意义(P<0.05)。两组治疗期间均未出现严重不良反应。结论 采用利拉鲁肽联合短期胰岛素强化治疗初诊肥胖2型糖尿病患者效果显著,利于控制患者血糖水平,降低炎症因子,临床应用安全性较高。

Objective To investigate the clinical efficacy of liraglutide and short-term insulin intensive treatment on newly diagnosed obese patients with type 2 diabetes mellitus and its effect on inflammatory factors. Methods A total of 92 newly diagnosed obese patients with type 2 diabetes who were admitted to our hospital from June 2018 to June 2020 were selected as the research subjects, and they were divided into observation group and control group by random number table method, with 46 cases in each group. The control group was given short-term intensive insulin therapy, and the observation group was given liraglutide on the basis of the control group. The blood glucose(fasting blood glucose [FBG], 2 h postprandial blood glucose [2 h PBG]) levels, inflammatory factors(tumor necrosis factor [TNF-α], interleukin-6 [IL-6]) levels before and one month after treatment and adverse reactions between the two groups were compared. Results FBG([5.96±0.93] mmol/L), 2 h PBG([7.28±1.25] mmol/L), TNF-α([56.16±8.07] ng/L), IL-6([311.87±28.51] ng/L) in the observation group were all lower than([7.38±1.25] mmol/L, [9.31±1.46] mmol/L, [68.24±10.74] ng/L,and [602.14±41.48] ng/L) in the control group, the differences were statistically significant(P<0.05). There were no serious adverse reactions in the two groups during treatment. Conclusion The intensive treatment of liraglutide and short-term insulin in newly diagnosed obese patients with type 2diabetes mellitus is effective, which is beneficial to control the blood sugar level and reduce inflammatory factors, and the clinical application is safe.